城区与偏远山区复治耐多药肺结核的临床疗效比较  

Comparing the clinical efficacy between the city area and secluded mountain area in MDR-TB

作　　者：姚永秀[1] 杨晓梅[1] 刘娅 

机构地区：[1]重庆市肺科医院,400020 [2]重庆市结核病防治所

出　　处：《临床肺科杂志》2005年第4期453-454,共2页Journal of Clinical Pulmonary Medicine

摘　　要：目的比较重庆市城区和偏远山区复治耐多药肺结核接受以KPO1321为主的抗痨方案疗效的差异。方法回顾性总结91例复治耐多药患者接受该方案试疗3～6月的痰菌阴转率,比较两者的差异。结果城区50例,3月痰菌阴转率为44%,6月为66%;偏远山区41例,3月痰菌阴转率为73.17%,6月为85.36%,二者比较有显著性差异。结论偏远山区复治耐多药肺结核对该方案的疗效明显优于城区。Objective To compare the clinical efficacy between the city area and the secluded mountain area with the project of KOPTH 1321 in treating MDR-TB. Methods A total of 91 patients with MDR-TB treated for 3~6 months with the drugs. Results The sputum M. tuberculosis clearance rates were 44% in the city and 73.17% in the mountain area after 3 months (P<0.01), 66% in the city and 85.36% in the mountain area (P<0.05) after 6 months. There were singnificant differences in the two groups in the rate comparisons.Conclusion The clinical efficacy of MDR-TB in secluded mountain area is better than that in the city area.

关 键 词：耐多药肺结核 抗痨方案 耐药率 杀菌药 

分 类 号：R521[医药卫生—内科学] R978.3[医药卫生—临床医学]